Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:526 (15 September), doi:10.1136/bmj.39310.506308.AD
Evidence on its benefits and harms is available but is being ignored
| The first 150 words of the full text of this article appear below. |
The promotion of prescription drugs to the public ("direct to consumer advertising") is currently used only in the United States and New Zealand. A systematic review of the clinical and economic consequences confirmed that this form of advertising influences patient demand and doctors' prescribing behaviour, but evidence of health benefits or improvements in underuse was lacking.1 A more recent report from the Institute of Medicine confirmed that direct to consumer advertising increases the early use of new drugs and asked for a two year moratorium of such advertising for newly approved drugs.2 Requests were made to revise the legislation towards limiting or even banning such advertising both in the US and in New Zealand3 4 after rofecoxib (a heavily advertised drug) was withdrawn from the market because it increased heart attacks.5 A proposal to modify the current ban on direct to consumer advertising will be considered by the European parliament in
Nicola Magrini, clinical pharmacologist1, Maria Font, pharmacist2
1 CeVEAS, NHS Centre for the Evaluation of the Effectiveness of Health Care, Modena Local Health Authority, 41100 Modena, Italy , 2 International Society of Drug Bulletins, Pharmaceutical Department, Verona Local Health Authority, 37122 Verona, Italy
n.magrini@ausl.mo.it
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.